Compare LifeStance Health Group Inc. Common Stock (LFST) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LifeStance Health Group Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.69B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: LifeStance Health Group Inc. Common Stock and Travere Therapeutics Inc. Common Stock are close in size by market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LFST | TVTX | |
|---|---|---|
Market Cap | $4.69B | $4.88B |
Volume | 1,858,220 | 1,668,577 |
Sector | Health | Health |
52-Week High | $13.38 | $67.52 |
52-Week Low | $4.81 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.92B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LifeStance Health Group Inc. Common Stock
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
